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Abstract
Background:  Together single nucleotide substitutions and small insertion/deletion variants are the most
common form of sequence variation in the human gene pool.
High-resolution SNP profile and/or haplotype analyses enable the identification of modest-risk susceptibility genes
to common diseases, genes that may modulate responses to pharmaceutical agents, and SNPs that can affect
either their expression or function. In addition, sensitive techniques for germline or somatic mutation detection
are important tools for characterizing sequence variations in genes responsible for tumor predisposition. Cost-
effective methods are highly desirable. Many of the recently developed high-throughput technologies are geared
toward industrial scale genetic studies and arguably do not provide useful solutions for small laboratory
investigator-initiated projects. Recently, the use of new fluorescent dyes allowed the high-resolution analysis of
DNA melting curves (HRM).
Results: Here, we compared the capacity of HRM, applicable to both genotyping and mutation scanning, to detect
genetic variations in the tumor suppressor gene TP53 with that of mutation screening by full resequencing. We
also assessed the performance of a variety of available HRM-based genotyping assays by genotyping 30 TP53 SNPs.
We describe a series of solutions to handle the difficulties that may arise in large-scale application of HRM to
mutation screening and genotyping at the TP53 locus. In particular, we developed specific HRM assays that render
possible genotyping of 2 or more, sometimes closely spaced, polymorphisms within the same amplicon. We also
show that simultaneous genotyping of 2 SNPs from 2 different amplicons using a multiplex PCR reaction is feasible;
the data can be analyzed in a single HRM run, potentially improving the efficiency of HRM genotyping workflows.
Conclusion: The HRM technique showed high sensitivity and specificity (1.0, and 0.8, respectively, for amplicons
of <400 bp) for mutation screening and provided useful genotyping assays as assessed by comparing the results
with those obtained with Sanger sequencing. Thus, HRM is particularly suitable for either performing mutation
scanning of a large number of samples, even in the situation where the amplicon(s) of interest harbor a common
variant that may disturb the analysis, or in a context where gathering common SNP genotypes is of interest.
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Background
Together Single Nucleotide Polymorphisms (SNPs), rare
single nucleotide substitutions, and small insertion/dele-
tion mutations constitute the most common forms of
sequence variation in the human genome. For example,
Nickerson et al. [1] have estimated that the density of
common SNPs (with a frequency greater than 1%) is
about 1 per 300 bp in the overall human gene pool. Fur-
thermore, deep resequencing studies have demonstrated
that the number of rare single nucleotide substitutions
and small insertion/deletion variants vastly outnumber
common SNPs [2,3].
During the last decade, SNPs have essentially replaced
microsatellites for linkage and/or association studies [4,5]
and genome-wide association studies with phase 2 and
phase 3 confirmations have now provided overwhelming
evidence of association on common SNPs with a number
of diseases [6,7]. SNPs are also becoming of interest in
pharmacogenetics, because some of them are associated
with significant differences in biological response to phar-
maceutical agents [8,9].
Heavy interest in SNPs has led to the development of dif-
ferent genotyping methods: some of them are targeted to
the analysis of one or few SNPs [10,11], and others are
designed to scan the whole genome [12,13]. Modern gen-
otyping equipment has driven the per genotype cost for
very large-scale SNP genotyping studies quite low. In addi-
tion, clonal sequencing technologies may drive the cost of
moderate sensitivity resequencing studies very low
[14,15]. However, these technologies are actually geared
to what are essentially industrial scale genetic studies and
arguably to not provide useful solutions for small labora-
tory investigator-initiated projects.
Interest in fast and reliable methods of mutation screen-
ing is increasing as well. Such methods are desirable for
case-control mutation screening studies and high-
throughput somatic (tumor) mutation screening studies
[16,17], aiding the identification of new genes involved in
carcinogenesis. They are also desirable for detecting genes
responsible for drug-resistance in micro-organisms [18],
and for detecting genes that modify growth, resistance to
parasites, or yield in plants [19].
Many techniques have been developed to discover
genomic variation, including those based on HPLC (High
Performance Liquid Chromatography), electrophoretic
conformational changes, and enzymatic or chemical
cleavage reactions [20]. The goal of these screening tech-
niques is to reduce the use of DNA sequencing and con-
trol costs while maintaining sensitivity and specificity.
The HRM technique has been used to mutation scan the
coding sequences of several clinically important genes
[21-26]. For instance, 3 studies have reported mutation
screening of TP53 exonic regions [21,22,27]. In this man-
uscript, we describe lessons learned from a larger scale
application of HRM to mutation screening and genotyp-
ing at the entire TP53 locus. First, we assayed (in terms of
sensitivity and specificity) the HRM technique, by com-
paring the results with the classic Sanger sequencing
method, used here as the gold standard reference. Second,
we propose solutions for genotyping challenges (discrim-
ination of the 3 genotypes, simultaneous genotyping of 2
or more SNPs) that are sometimes encountered when
using a classical HRM approach.
Methods
Origin of DNA samples
Mutation screening of the entire TP53  locus was per-
formed on 47 DNA samples including lymphocyte DNA
from 25 Li-Fraumeni patients, DNA from lymphoblastoid
cell lines derived from 15 familial breast cancer patients,
and DNA from 7 hemizygous (at the TP53 locus) breast
tumor cell lines (Garritano et al, in preparation).
Genotyping of 30 SNPs located within the TP53 locus was
performed on 270 DNA samples from the Coriell Reposi-
tory, corresponding to 90 Caucasians, 90 East Asians, and
90 Africans.
This mutation screening and genotyping project received
approval from the IARC Institutional Review Board and
from the Brazilian center from which we received the Li-
Fraumeni patient samples. It was conducted according to
the Declaration of Helsinki Principles.
Mutation screening/SNP discovery using HRM
PCR was performed in 8 μl reactions containing 20 ng of
template DNA, 1.5 mM MgCl2, 265 μM dNTP, 400 nM
forward and reverse primers, 0.8X LCGreen® Plus (Idaho
Technology, Salt Lake City, Utah, USA), 0.04 U/μl of Plat-
inum® Taq Polymerase, and 1× PCR buffer supplied by the
manufacturer (Invitrogen, Paisley, Scotland).
The HRM process consists in performing the PCR in the
presence of the DNA binding dye LC Green®, monitoring
the progressive change in fluorescence caused by release
of the dye from a DNA duplex as it is denatured by
increasing the temperature, collecting a high resolution
melting curve, and identifying the samples with melting
curve aberrations indicative of the presence of a sequence
variant. Fluorescence intensity as a function of tempera-
ture, monitored by the LightScanner® instrument (Idaho
Technology, Salt Lake City, Utah, USA), can reveal very
small changes in the melting curve shape, when analyzed
with the LightScanner®  software using the "Scanning"
mode (Idaho Technology, Salt Lake City, Utah, USA).BMC Genetics 2009, 10:5 http://www.biomedcentral.com/1471-2156/10/5
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Genotyping using HRM
We designed pairs of primers flanking each SNP [See
Additional file 1] to amplify DNA fragments shorter than
400 bp. In some instances, HRM can directly discriminate
all 3 genotypes (common homozygotes, heterozygotes
and rare homozygotes) of a polymorphism. However, for
the majority of TP53 amplicons, genotyping using spike-
in control DNA was performed to allow distinction of rare
homozygotes from common homozygotes. In brief,
genomic DNAs were mixed with an equal amount of DNA
from a known major allele homozygous subject to allow
formation of heteroduplexes. This strategy converts the
minor allele homozygotes into heterozygotes, rendering
them distinguishable from the major allele homozygous
samples. The scoring of genotypes obtained with spike-in
experiments was managed via automated procedures. For
instance, we have developed a Laboratory Information
Management Systems (LIMS) where results generated
from a standard HRM genotyping plate and a correspond-
ing spike-in genotyping plate are automatically converted
into a final genotype call [28]. The program is also capable
of rejecting samples that show unacceptable calls.
For amplicons containing two or more SNPs, sensitivity of
mutation scanning may be decreased by producing com-
plex melting curve data, and a different genotyping strat-
egy had to be applied. This second strategy relies on an
unlabelled probe-based genotyping analysis followed by
mutation scanning, where the probe is designed to target
the SNP(s) of interest. Both probe-amplicon duplex and
whole amplicon duplex melting regions can be observed
from the same melting run, in two distinct temperature
windows, allowing genotyping and mutation scanning
analyses to be performed simultaneously. Stratification of
the samples according to their genotypes at the common
variant positions prior to mutation scanning analysis
reduces the noise and enhances the sensitivity for the
detection of rare or unknown variants.
In practice, unlabeled 3' blocked probes targeting each
common SNP were designed. PCR were performed in
presence of a DNA dye (Here LC Green®) and oligonucle-
otides serving as probes were blocked at the 3' end to pre-
vent extension during amplification. All genotyping
assays were performed as a nested PCR, to ensure a good
amplification of the region of interest. The primary PCR
used standard conditions, whereas the secondary PCR
included the unlabelled probe (500 nM) and was asym-
metric so that more copies of the strand to which the
probe anneals were produced. The ratio between the
nested PCR primers was 1:5 (100 nM:500 nM) with an
excess of the primer for the strand that is complementary
to the probe. This favours probe-target annealing and
reduces competition with the complementary strand [29].
Thus, this protocol produced sufficient double-stranded
product for amplicon melting and enough single stranded
product for probe annealing [30]. The analysis proceeds
in two steps. The first step consists in analyzing the melt-
ing curve in the region corresponding to the probe Tm.
This step stratifies the samples into three groups based on
the genotypes of the common SNP. The second analysis
step consists in performing mutation scanning of the gen-
otype-defined subgroups in the region corresponding to
the amplicon Tm, to identify the samples that are hetero-
zygous for any rare sequence variants. For the amplicon
containing SNPs rs9894946 (common) and rs17883532
(rare) the probe was designed to perfectly complement
the rs9894946 T allele (GGAGCTCAGTACTGCCTGCCC,
the variable nucleotide is indicated in bold). For the
amplicon containing SNPs rs858528, rs1641548, and
rs1641549, two probes were designed. The first probe was
designed to perfectly complement the rs858528 G allele
(GCAGAGCGAGACTCAAAA). The second probe was
designed to complement the rs1641548 G allele and
rs1641549 A allele (TTAACCGGGCATGATGGCAG, the
variable nucleotides corresponding to SNPs rs1641548
and rs1641549 are indicated in bold). Probes were
designed to have different Tm (63°C and 54°C, respec-
tively), in order not to interfere with each other in the
melting data analysis.
Results
Mutation Scanning
During the course of a project to mutation screen the
entire TP53 locus by direct resequencing from a set of 47
samples, we took delivery of a High Resolution Melt
instrument. To assess the sensitivity and specificity of
HRM for mutation scanning, we undertook mutation
screening of the last 21 TP53 amplicons and of 1 ampli-
con corresponding to the proximal promoter region of the
gene (from a total of 67 amplicons) by both full-sequence
resequencing and HRM in a single pass experiment (Table
1).
Nine of the amplicons were <400 bp in length, with an
average length of 286 bp. For these, the sensitivity and
specificity of HRM for sequence variant detection were 1.0
(38 true positive/(38 true positive + 0 false negative)), and
0.83, (295 true negative/(60 false positive + 295 true neg-
ative)), respectively.
Thirteen of the amplicons were >400 bp in length, with an
average length of 544 bp. For these, the sensitivity and
specificity of HRM for sequence variant detection were
0.81 (105 true positive/(105 true positive + 23 false nega-
tive)), and 0.84, (339 true negative/(69 false positive +
339 true negative)), respectively. Of note, the variant
rs17551157, insertion of a cytosine following a 7 cytosine
mononucleotide run in the TP53 promoter region, was
undetectable in an amplicon of 653 bp.BMC Genetics 2009, 10:5 http://www.biomedcentral.com/1471-2156/10/5
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The joint dropout rate from PCR, sequencing, and or
HRM was 6.8%. Neither PCR-sequencing nor PCR-HRM
had a single pass dropout rate exceeding 5%, thus staying
above our general research mutation screening success
rate target of 95%.
Genotyping
We performed genotyping of 30 SNPs located within the
TP53 locus on 270 DNA samples from the Coriell Repos-
itory.
In some cases, it was possible to distinguish directly the
three different genotypes of a SNP using standard HRM
analysis of the amplicon of interest. Figure 1 displays the
melting curve analysis of the SNP rs9903378, a T>G sub-
stitution. In this experiment, it was possible to discrimi-
nate the three groups corresponding to each genotype
directly (common homozygotes TT, heterozygotes TG,
and rare homozygotes GG) (Figure 1). This SNP resides in
a T-rich sequence that has a low melting temperature. The
GG samples have a melting curve different from the com-
mon homozygotes TT; evidently, the G interrupts the long
poli-Ts and markedly increases the melting point of the
amplicon.
However, we found direct detection of minor allele
homozygotes to be the exception rather than the rule, at
least when using the mutation scanning approach for
amplicons in the 200 bp to 400 bp length range. In this
context, spike-in experiments provided an approach to
detection of minor allele homozygotes. As an example,
melting analyses for the SNP rs17881035 are displayed in
Figure 2 (panels A, B). Applying standard melting curve
analysis (Figure 2A), we observed that the heterozygous
AG samples have a distinct melting curve profile com-
pared to the common homozygote AA samples. However,
the minor allele homozygote GG samples were not distin-
guished from the common homozygous AA samples
because the difference between their Tm was insufficient.
In a second experiment (Figure 2B), each sample was
mixed with an equal quantity of DNA from an AA
homozygote (a pre-PCR spike-in experiment). This strat-
egy in effect converts the minor allele GG homozygotes
into GT heterozygotes, rendering them distinguishable
from AA samples. In some instances, HRM can directly
discriminate all of the genotypes of an amplicon that con-
tains two SNPs. As an example, a 130 bp amplicon carry-
ing SNPs rs17880560 and rs1614984 is displayed on
Figure 3.
Nevertheless, we have encountered examples where HRM
cannot discriminate heterozygous samples for SNP1 from
heterozygous samples for SNP2. In Figure 4 (panels A, B,
C), we present an example and solution for an amplicon
that contains two SNPs (rs9894946 and rs17883532) not
directly distinguishable from each other. Heterozygous
samples for either the first or the second SNP show almost
indistinguishable melting curves (Figure 4A). We then
Table 1: Oligonucleotide primer sequences used for comparison of HRM and sequencing sensitivity and specificity.
Amplicon Forward sequence 5'>3' Reverse sequence 5'>3' Location size
3 CGGGACGTGAAAGGTTAGAA TTTTGGGGTGGAAAATTCTG promoter 653
39 TGGCCATCTACAAGCAGTCA ACACGCAAATTTCCTTCCAC exon5-intron5 211
40 CATGAGCGCTGCTCAGATAG CAGTTGCAAACCAGACCTCA exon6 234
41 GTGGAAGGAAATTTGCGTGT TTGCACATCTCATGGGGTTA intron6 212
43 TGGCTCTGACTGTACCACCA TCTACTCCCAACCACCCTTG intron 7 371
44 CTGGAAGACTCCAGGTCAGG AGCTGTTCCGTCCCAGTAGA intron7 383
46 GCGCACAGAGGAAGAGAATC TGAAAGCTGGTCTGGTCCTT intron9 452
47 GCAGTGATGCCTCAAAGACA GCAGGCTAGGCTAAGCTATGA intron9 280
48 TGACTTTGCCTGATACAGATGC TAGCTACTGGGGAGGCAGAG intron9 596
49 GGCCTGCCTAGCCTACTTTT GTAGCAGGCGCTTGTAGTCC intron9 578
50B GACTACAAGCGCCTGCTACC TTTCATGCAACCATGCTGTT intron9 614
51 CCCTACAGTTGGGCAAAGTC CGACTGTGCCTCGTTTCTTT intron9 491
52A CCTGGGCGATAGAGTGAGAC GGCTGGACTCAAACTCTTGG intron9 134
52B GTCGCATGCACATGTAGTCC CTTGAGTTCCAAGGCCTCAT intron9 635
53 ACTTCTCCCCCTCCTCTGTT CCTGGGTTTGGATGTTCTGT exon10-intron10 348
55 TATACTCAGCCCTGCCATGC GGACTTCAGGTGGCTGTAGG intron10 603
57 TTTGGGTCTTTGAACCCTTG GTGGTTTCAAGGCCAGATGT exon11 (3'UTR) 400
58 GGCCCACTTCACCGTACTAA AAGCGAGACCCAGTCTCAAA exon11 (3'UTR) 485
59 AAGGAAATCTCACCCCATCC AAATGCAGATGTGCTTGCAG exon11 (3'UTR) 456
60 TTGAGACTGGGTCTCGCTTT CAGTCTCCAGCCTTTGTTCC 566
61 AAAACTTTGCTGCCACCTGT ATCCTGCCACTTTCTGATGG 415
62 GCCTCTCACCAAGGATTACG CCTGGACAGTAGCACCCACT 535BMC Genetics 2009, 10:5 http://www.biomedcentral.com/1471-2156/10/5
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designed an unlabeled 3' blocked probe that hybridizes to
the region of sequence specific for the more common SNP
rs9894946 [31]. Results are displayed in Figure 4 panels B,
C. The first analysis step stratifies the samples into three
groups based on the genotypes of rs9894946 (Figure 4B).
In a second analysis step, mutation scanning of the geno-
type-defined subgroups in the region corresponding to
the amplicon Tm is performed, in order to identify the
samples that are heterozygous for any other rare sequence
variants. In this example, we found three heterozygous
subjects for the SNP rs17883532 in 270 samples (Figure
4C). All these heterozygous subjects were homozygous for
the major allele of SNP rs9894946. This solution is accept-
able only if the second SNP is rare because the mutation
scanning applied after the stratification of samples accord-
ing the melting profile of the common SNP targeted by
the unlabeled probe may not distinguish rare from com-
mon homozygous samples.
Genotyping of SNP rs9903378 Figure 1
Genotyping of SNP rs9903378. The three groups are well distinguished: TT in grey, GG in red and TG in blue.BMC Genetics 2009, 10:5 http://www.biomedcentral.com/1471-2156/10/5
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During the course of our TP53 study, we faced another
particular situation, where two or more common SNPs lie
in the same amplicon. In such a case, it may be necessary
to use more than one unlabelled probe. For instance, one
of our TP53 amplicons contains two SNPs: rs1641548 and
rs1641549. These are only 4 bp apart, and both are A-to-
G variants. Samples that are heterozygous for either the
first or the second SNP have essentially indistinguishable
melting curves (Figure 5A). Moreover, this amplicon also
contains the SNP rs858528. In this case, two probes were
designed. The first probe was designed to perfectly com-
plement the rs858528 G allele. The second probe was
designed to complement the rs1641548 G allele and
rs1641549 A allele. Thus, homozygotes for the rs858528/
rs1641548/rs1641549 haplotype G-G-A match both
probes exactly and therefore have the highest Tm across the
compound-melting interval. Figure 5B and 5C show vari-
ous genotypes combinations of the three SNPs found in
our sample series.
Finally, we evaluated whether the different genotypes
from 2 independent PCR products could be discriminated
from one single melting curve analysis. Since the ampli-
con containing SNP rs9903378 (which can be directly
genotyped, see Figure 1) and the amplicon containing
SNP rs9894946 (for which a specific probe had to be
designed, see Figure 4) showed different Tm (range 75–
80°C and 90–95°C, respectively), they were selected to
conduct the experiment. Both SNP containing fragments
were amplified in a single PCR, and HRM analysis was
conducted on the multiplex PCR product. In this last
experiment, conditions of the multiplex PCR slightly dif-
fered from conditions of the simplex PCR, in order to
achieve simultaneous amplification of both amplicons in
a single reaction. In particular, the primer concentration
for the amplicon containing the rs9903378 was decreased
from 400 nM to 300 nM because at higher concentration
only this amplicon was amplified (data not shown). Melt-
ing curves of the multiplex PCR products showed different
patterns depending on the genotype combinations for the
Genotyping using spike-in control DNA to distinguish common homozygotes from rare homozygotes Figure 2
Genotyping using spike-in control DNA to distinguish common homozygotes from rare homozygotes. A. The 
melting curves of AG heterozygotes (in red) are distinguished from homozygous AA (in grey). Homozygous GG samples (in 
blue) are not distinguished from the common AA homozygous samples.B After spike-in of a homozygous AA sample, the GG 
samples are converted into AG heterozygotes (in blue), and they are now distinguished from AA samples.BMC Genetics 2009, 10:5 http://www.biomedcentral.com/1471-2156/10/5
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Simultaneous genotyping of two or more SNPs within the same amplicon using the classic HRM approach Figure 3
Simultaneous genotyping of two or more SNPs within the same amplicon using the classic HRM approach. 
There are two SNPs in this amplicon: rs17880560 and rs1614984. In grey, samples homozygous for both SNPs; in red, samples 
homozygous for rs17880560 (delCACGGC/delCACGGC) and heterozygous for rs1614984 (C/T). In blue, samples 
homozygous for rs1614984 (C/C) and heterozygous for rs17880560 (insCACGGC/delCACGGC). In green, samples hetero-
zygous for both SNPs.BMC Genetics 2009, 10:5 http://www.biomedcentral.com/1471-2156/10/5
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2 SNPs (Figure 6). Using the "genotyping" mode of Light-
Scanner® software, it was possible to distinguish them
from each other in a single melting curve analysis (Figure
6A). However, especially when analyzing a large number
of samples (>80), resolution can be improved by perform-
ing the HRM analysis of the multiplex PCR products in
two steps, that is by analyzing the 2 melting regions corre-
sponding to the 2 DNA fragments separately (Figure 6B
and 6C). Thus, our results demonstrate that HRM geno-
typing of multiplex PCR products is feasible and cost and
time effective.
Discussion
In this manuscript, we assessed the sensitivity and specifi-
city of HRM for mutation screening by comparing it head
to head with the direct resequencing of 21 TP53 locus
amplicons on 47 DNA samples. A second application of
the HRM analysis was the genotyping of 30 known SNPs
within this gene on 270 DNA samples.
In mutation scanning mode, the sensitivity and specificity
of HRM were 1.0 and 0.80, respectively, for amplicons of
<400 bp, and 0.81 and 0.84, respectively, for amplicons of
>400 bp.
Recent studies have validated HRM for screening of
number genes of clinical significance [21-26]. These stud-
ies also reported a sensitivity of HRM close to 100%,
except in the situation were amplicons have a high GC
content [26]. We also encountered a similar situation with
one TP53 GC-rich amplicon (see below). However, in the
previous studies, the HRM technique was evaluated only
Simultaneous genotyping of common SNP rs9894946 and rare SNP rs17883532 Figure 4
Simultaneous genotyping of common SNP rs9894946 and rare SNP rs17883532. A. In mutation scanning mode, 
heterozygous samples for either the first (in red) or the second SNP (in green) have virtually indistinguishable melting curves. 
B. In genotyping mode using an unlabeled probe for rs9894946, the 3 genotypes are distinguisable (CC in gray, CT in red, TT 
in blue). C. Mutation scanning of homozygous rs9894946 CC subset reveals heterozygous rs17883532 CT (In green).BMC Genetics 2009, 10:5 http://www.biomedcentral.com/1471-2156/10/5
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on partial or full coding sequence(s) of the genes of inter-
est. For instance, more than 80% of TP53 mutation stud-
ies focus on exons 5–8 (residues 126–306) because most
mutations are localized in the DNA binding domain of
the protein (residues 100–300) [21,22]. However, in one
study where the HRM analysis was extended to the entire
coding exon of TP53, 41% of the alterations fall outside
exons 5–8 [22]. Thus partial scanning of TP53 sequence
may lead to a bias in the mutation analysis. Following this
idea, we aimed to evaluate a set of HRM assays that sam-
ple the entire TP53 locus, including one or more ampli-
cons from the proximal promoter, coding exons, introns,
and 3' UTR. Our study thereby provides a broader view of
the strengths and limitations of HRM-based techniques.
However, the TP53 amplicons used in the present study
were not designed specifically for HRM but rather for
mutation screening of the entire TP53 locus by direct rese-
quencing in the context of a Li-Fraumeni syndrome-
related study (Garritano et al, in preparation). Conse-
quently, some of the amplicons were longer than the opti-
mum for HRM mutation scanning. Nonetheless, we have
shown that the sensitivity of HRM for mutation screening
is very high, especially for amplicons <400 bp.
For genotyping applications, especially for intronic SNPs,
primers were sometimes designed quite far from the SNP
of interest to avoid unspecific amplification. Despite the
length of the amplicons used, we obtained full concord-
ances between HRM genotyping calls and results of direct
sequencing. Moreover, using an amplicon of >400 bp, we
Simultaneous genotyping of rs858528, rs1641548, and rs1641549 using two unlabeled probes Figure 5
Simultaneous genotyping of rs858528, rs1641548, and rs1641549 using two unlabeled probes. A Samples that are 
heterozygous for rs858528, rs1641548, and rs1641549 have essentially indistinguishable melting curves (in red). B Genotyping 
using two unlabeled probes. Probe 1 targets the G allele of rs858528 and probe 2 targets the G allele of rs1641548 and the A 
allele of rs1641549. C Each distinct melting profile from panel B corresponds to a combination of genotypes of the three SNPs 
found in our population.BMC Genetics 2009, 10:5 http://www.biomedcentral.com/1471-2156/10/5
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succeeded to simultaneously genotype two SNPs located
approximately 200 bp apart from each other (SNP
rs858528 and rs1641549), thus reducing the number of
PCR reactions and improving time and cost effectiveness.
In mutation scanning mode, HRM tended to call as "vari-
ant" some DNA samples that actually were wild type. To
minimize the frequency of false positive "variant" calls, it
is recommended to standardize DNA preparation, storage
methods, and storage conditions. Because the sensitivity
and specificity of HRM are exquisitely dependent on the
melting temperature of each individual sample, variation
in salt or buffer concentration carried into PCR reactions
along with substrate DNA can generate heterogeneous
melting profiles. If needed, to reduce sample-to-sample
heterogeneity, it can also be useful to perform a nested
PCR and the HRM assay on the secondary PCR.
In the course of our work, we have observed one potential
weakness in HRM: the technique may have limited sensi-
tivity for single nucleotide insertion-deletion variants
located immediately adjacent to mononucleotide runs of
sufficient length that they stutter during PCR. In this work,
SNP rs17551157, an insertion of a cytosine adjacent to a
7 cytosine repeat within TP53 proximal promoter, was
undetectable in a 653 bp HRM amplicon. A similar situa-
tion was also encountered during a large-scale case/con-
trol mutation scanning of ATM  performed in our
laboratory, where insertion of an adenosine adjacent to an
intronic run of 10 thymines (rs3218681) was also unde-
An amplicon containing rs9903378 and an amplicon containing rs9894946 were amplified in a multiplex PCR Figure 6
An amplicon containing rs9903378 and an amplicon containing rs9894946 were amplified in a multiplex PCR. 
A The melting curves of the different genotype combinations of the two SNPs show different profiles. In gray TT-CC, in blue 
TT-CT, in red GG-CC, in orange TG-CC and in purple TT-TT, respectively for rs9903378 and rs9894946. B The analysis was 
performed in the region of melting temperature of rs9903378 (75–80°C). in gray TT, in orange TG in red GG. C The analysis 
was performed in the region of melting temperature of rs9894946 (90–95°C). in gray CC, in blue CT in purple TT.BMC Genetics 2009, 10:5 http://www.biomedcentral.com/1471-2156/10/5
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tectable by HRM mutation scanning. In both cases, the
sequencing chromatograms revealed PCR stuttering at the
mononucleotide run (data not shown). Such mononucle-
otide runs are relatively uncommon within the ORF of
protein coding genes. Nonetheless, we suggest that at the
outset of an HRM based mutation-screening project,
investigators check the ORF of the gene of interest for
mononucleotide runs that could create such a problem. If
any are present, apply a different mutation screening tech-
nique to the relevant amplicon.
From our extensive mutation screening of the TP53 locus,
we found that HRM provides sensitive assays both for
detection of new sequence variants and genotyping of
known polymorphisms. Table 2 summarizes the various
HRM approaches for the different genetic contexts that we
have considered, according to the number of SNPs present
in each amplicon and to their frequencies in the studied
population. In our experience, selecting an appropriate
HRM analysis strategy depends both on study size and the
number of known common polymorphisms in a given
amplicon. For relatively small mutation screening studies,
it may be reasonable to sequence all samples that appear
to contain a sequence variant. In this case, amplicons
known (or found) to contain a common variant can be
PCR amplified in duplicate, once as a standard analysis
and once as a spike-in analysis. The former will detect the
presence of heterozygous variants and the latter will detect
the presence of minor allele homozygotes. All samples
with HRM curves that differ from the major allele
homozygotes curves would then be queued for sequenc-
ing.
In large-scale mutation screening studies, there may be
cost benefit to enabling HRM determination of common
SNP genotypes prior to mutation scanning, so that only
samples showing a variant HRM curve not attributable to
the presence of a common SNP are queued for sequenc-
ing.
If an amplicon contains a common variant, this variant
can mask the presence of a rare variant that might have the
same melting profile. Without a discrimination step, one
has to either 1) sequence all the heterozygous samples,
even though most will be due to a common SNP or 2)
accept failure to detect rare variants that have the same
melting profile as the common SNP. Inclusion of a dis-
crimination step, which can be achieved with little added
cost and with no extra PCR reactions, allows assigning the
common SNP by genotyping and simultaneously queuing
the rare variant heterozygotes for identification by
sequencing.
Conclusion
HRM is a simple and cost effective post-PCR technique
that can be used for high-throughput mutation scanning
and genotyping in a small laboratory environment. It is
inexpensive, flexible, and only mildly constrained by
primer design. HRM reactions are closed-tube, which
reduces risk of contamination. In addition, HRM assays
are non-destructive so that the actual sample used in
mutation scanning can serve as a sequencing template.
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